Cardax, Inc. (CDXI)
CDXI Stock Price Chart
Explore Cardax, Inc. interactive price chart. Choose custom timeframes to analyze CDXI price movements and trends.
CDXI Company Profile
Discover essential business fundamentals and corporate details for Cardax, Inc. (CDXI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 Mar 2013
Employees
10.00
Website
https://www.cardaxpharma.comCEO
David G. Watumull
Description
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.
CDXI Financial Timeline
Browse a chronological timeline of Cardax, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 14 May 2021
EPS came in at -$1.74 , while revenue for the quarter reached $104.57K .
Earnings released on 31 Dec 2020
EPS came in at -$1.79 , while revenue for the quarter reached $195.11K .
Earnings released on 13 Nov 2020
EPS came in at -$1.79 , while revenue for the quarter reached $66.50K .
CDXI Stock Performance
Access detailed CDXI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.